Gedea Biotech has been granted a patent by the United States Patent and Trademark Office for the treatment of fungal infections by the company’s compound glucono-δ-lactone (GDL).

The patent can be kept in force until 2037, states the company in a press release.

“The US market for treatment of vaginal infections is worth at least $300 million. Thus, the patent covering treatment and prevention of vaginal fungal infections by GDL, or pHyph strengthens Gedea’s position in one of the largest markets for treatment of these conditions. We think pHyph will replace a substantial share of the antimicrobials used for vaginal infections today,” says Annette Säfholm, Gedea Biotech’s CEO.

Previously been granted a patent in Eurasia

Gedea Biotech has previously been granted a patent in Eurasia (including Russia) for treatment of vaginal fungal infections using GDL (pHyph). A similar patent application is currently under evaluation by the European Patent Office (EPO) and expected to be allowed later this year.

In previous clinical studies, Gedea Biotech has demonstrated promising results with pHyph for treatment of bacterial vaginosis. In addition, a confirmatory, placebo-controlled trials currently being conducted at several European sites.

Photo of Annette Säfholm, Gedea